Clinical trial
A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
NCT05901987 is registered in ClinicalTrials.gov with GeneCradle Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
- Lead sponsor
- GeneCradle Inc
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- August 1, 2023
- Completion date
- December 31, 2028
- Enrollment
- 33 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
sma ii